Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M

HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended December 31, 2025. Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.